Novartis AG
SIX:NOVN

Watchlist Manager
Novartis AG Logo
Novartis AG
SIX:NOVN
Watchlist
Price: 107.08 CHF 0.19% Market Closed
Market Cap: 205.5B CHF

Novartis AG
Retained Earnings

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Novartis AG
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
Novartis AG
SIX:NOVN
Retained Earnings
$43.6B
CAGR 3-Years
-10%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
NLS Pharmaceutics AG
NASDAQ:NLSP
Retained Earnings
-$74.4m
CAGR 3-Years
-21%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Roche Holding AG
SIX:ROG
Retained Earnings
CHf43B
CAGR 3-Years
6%
CAGR 5-Years
2%
CAGR 10-Years
6%
S
Sandoz Group AG
SIX:SDZ
Retained Earnings
$7.9B
CAGR 3-Years
-1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Novartis AG
Glance View

Nestled in the heart of Europe's pharmaceutical landscape, Novartis AG has firmly etched its presence as a beacon of innovation and scientific prowess. This Swiss multinational behemoth, headquartered in Basel, operates at the confluence of research-driven development and cutting-edge technology. At its core, Novartis is devoted to discovering novel therapeutics and delivering them to patients across the globe. The company’s operations span various segments, with Pharmaceuticals and Oncology standing as the pillars of its revenue model. Through these divisions, Novartis vigorously pursues advancements in the treatment of diseases, focusing on areas such as cardiovascular, immunology, neuroscience, respiratory, and oncology. The innovative medicines they develop emerge from robust pipelines bolstered by strategic investments in research and development, propelling them to the forefront of healthcare innovation. Moreover, Novartis leverages a synergy between its Sandoz division, which is known for a strong generics and biosimilars portfolio, and its advanced therapeutic areas in Pharmaceuticals. This duality not only makes the company versatile but also resilient in the face of market volatilities. Unlike many pharmaceutical giants, Novartis prioritizes a hybrid approach by combining cutting-edge biotechnology with a stronghold in cost-effective generics. This model allows Novartis to cater to both the high-margin, innovation-driven segments and the volume-based, lower-margin arenas. Ultimately, their strategic focus is not just on creating the next blockbuster drug but on improving access to healthcare solutions globally, thereby reinforcing its revenue engine while delivering on its mission to reimagine medicine.

NOVN Intrinsic Value
112.64 CHF
Undervaluation 5%
Intrinsic Value
Price

See Also

What is Novartis AG's Retained Earnings?
Retained Earnings
43.6B USD

Based on the financial report for Sep 30, 2025, Novartis AG's Retained Earnings amounts to 43.6B USD.

What is Novartis AG's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
-4%

Over the last year, the Retained Earnings growth was 2%. The average annual Retained Earnings growth rates for Novartis AG have been -10% over the past three years , -4% over the past five years .

Back to Top